# US 2009/0269342 A1 · Hemagglutinin Polypeptides, and Reagents and Methods Relating Thereto

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0269342 A1
- Document ID: US20090269342A1
- Status: Published application
- Kind: A1
- Application number: 12/348,266
- Filed: 2009-01-02
- Published: 2009-10-29
- Earliest claimed: 2006-08-14
- Assignees: Massachusetts Institute of Technology
- Inventors: Ram Sasisekharan; Karthik Viswanathan; Aarthi Chandrasekaran; Rahul Raman; Aravind Srinivasan; S. Raguram; Viswanathan Sasisekharan
- Web page: https://patentgrep.com/patent/US20090269342A1

## CPC

- G01N 33/56983: {Viruses}
- C07K 14/005: from viruses
- C12N 2760/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- G01N 2333/11: Orthomyxoviridae, e.g. influenza virus
- G01N 2400/10: Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N 2500/02: Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides a system for analyzing interactions between glycans and interaction partners that bind to them. The present invention also provides HA polypeptides that bind to umbrella-topology glycans, and reagents and methods relating thereto.

## Claims

### Claim 1

An engineered binding agent that binds to umbrella-topology glycans.

### Claim 2 (depends on 1)

The engineered binding agent of claim 1, wherein the umbrella-topology glycans comprise α2-6 sialylated glycans.

### Claim 3 (depends on 1, 2)

The engineered binding agent of claim 1 or claim 2, wherein the binding agent binds to the umbrella-topology glycans with high affinity.

### Claim 4 (depends on 3)

The engineered binding agent of claim 3, wherein the binding agent binds to the umbrella-topology glycans with an affinity comparable to that of a wild-type human adapted HA that mediates infection of humans.

### Claim 5 (depends on 3)

The engineered binding agent of claim 3, wherein the binding agent binds to the umbrella-topology glycans with an affinity that is at least 50% that of a wild-type HA that mediates infection of humans.

### Claim 6 (depends on 3)

The engineered binding agent of claim 3, wherein the binding agent binds to the umbrella-topology glycans with an affinity that is at least 70% that of a wild-type HA that mediates infection of humans.

### Claim 7 (depends on 3)

The engineered binding agent of claim 3, wherein the binding agent binds to the umbrella-topology glycans with an affinity that is at least 80% that of a wild-type HA that mediates infection of humans.

### Claim 8 (depends on 3)

The engineered binding agent of claim 3, wherein the binding agent binds to the umbrella-topology glycans with an affinity that is at least 90% that of a wild-type HA that mediates infection of humans.

### Claim 9 (depends on 3)

The engineered binding agent of claim 3, wherein the binding agent binds to the umbrella-topology glycans with an affinity that is at least 100% that of a wild-type HA that mediates infection of humans.

### Claim 10 (depends on 1, 2)

The engineered binding agent of claim 1 or claim 2, wherein the binding agent binds to the umbrella-topology glycans preferentially as compared with cone-topology glycans.

### Claim 11 (depends on 10)

The engineered binding agent of claim 10, wherein the binding agent binds to umbrella-topology glycans vs cone-topology glycans with a relative affinity of at least 2.

### Claim 12 (depends on 10)

The engineered binding agent of claim 10, wherein the binding agent binds to umbrella-topology glycans vs cone-topology glycans with a relative affinity of at least 3.

### Claim 13 (depends on 10)

The engineered binding agent of claim 10, wherein the binding agent binds to umbrella-topology glycans vs cone-topology glycans with a relative affinity of at least 4.

### Claim 14 (depends on 10)

The engineered binding agent of claim 10, wherein the binding agent binds to umbrella-topology glycans vs cone-topology glycans with a relative affinity of at least 5.

### Claim 15 (depends on 10)

The engineered binding agent of claim 10, wherein the binding agent binds to umbrella-topology glycans vs cone-topology glycans with a relative affinity of at least 10.

### Claim 16

An isolated binding agent that binds to umbrella-topology glycans other than, which binding agent is not an H1 protein from any of the strains: A/South Carolina/1/1918; A/Puerto Rico/8/1934; A/Taiwan/1/1986; A/Texas/36/1991; A/Beijing/262/1995; A/Johannesburg/92/1996; A/New Caledonia/20/1999; A/Solomon Islands/3/2006, or an H2 protein from any of the strains: A/Japan/305+/1957; A/Singapore/1/1957; A/Taiwan 1/1964; A/Taiwan 1/1967, or an H3 protein from any of the strains: A/Aichi/2/1968; A/Phillipines/2/1982; A/Mississippi/1/1985; A/Leningrad/360/1986; A/Sichuan/2/1987; A/Shanghai/11/1987; A/Beijing/353/1989; A/Shandong/9/1993; A/Johannesburg/33/1994; A/Nanchang/813/1995; A/Sydney/5/1997; A/Moscow/10/1999; A/Panama/2007/1999; A/Wyoming/3/2003; A/Oklahoma/323/2003; A/California/7/2004; A/Wisconsin/65/2005.

### Claim 17

A characteristic portion of an engineered binding agent that binds to umbrella-topology glycans.

### Claim 18

A characteristic portion of a binding agent, which binding agent is not an H1 protein from any of the strains: A/South Carolina/1/1918; A/Puerto Rico/8/1934; A/Taiwan/1/1986; A/Texas/36/1991; A/Beijing/262/1995; A/Johannesburg/92/1996; A/New Caledonia/20/1999; A/Solomon Islands/3/2006, or an H2 protein from any of the strains: A/Japan/305+/1957; A/Singapore/1/1957; A/Taiwan/1/1964; A/Taiwan/1/1967, or an H3 protein from any of the strains: A/Aichi/2/1968; A/Phillipines/2/1982; A/Mississippi/1/1985; A/Leningrad/360/1986; A/Sichuan/2/1987; A/Shanghai/11/1987; A/Beiging/353/1989; A/Shandong/9/1993; A/Johannesburg/33/1994; A/Nanchang/813/1995; A/Sydney/5/1997; A/Moscow/10/1999; A/Panama/2007/1999; A/Fujian/411/2002; A/Wyoming/3/2003; A/Oklahoma/323/2003; A/California/7/2004; A/Wisconsin/65/2005, wherein the characteristic portion binds to umbrella-topology glycans.

### Claim 19 (depends on 17, 18)

A polypeptide comprising the characteristic portion of claim 17 or claim 18.

### Claim 20 (depends on 17, 18)

A nucleic acid encoding the characteristic portion of claim 17 or claim 18.

### Claim 21 (depends on 19)

A nucleic acid encoding the polypeptide of claim 19.

### Claim 22 (depends on 20)

A vector containing the nucleic acid of claim 20.

### Claim 23 (depends on 21)

A vector containing the nucleic acid of claim 21.

### Claim 24 (depends on 20)

A host cell containing the nucleic acid of claim 20.

### Claim 25 (depends on 21)

A host cell containing the nucleic acid of claim 21.

### Claim 26 (depends on 22)

A host cell containing the vector of claim 22.

### Claim 27 (depends on 23)

A host cell containing the vector of claim 23.

### Claim 28

An antibody that binds to an engineered binding agent that binds to umbrella-topology glycans.

### Claim 29

An antibody that binds to a binding agent, which binding agent is not an H1 protein from any of the strains: A/South Carolina/1/1918; A/Puerto Rico/8/1934; A/Taiwan/1/1986; A/Texas/36/1991; A/Beijing/262/1995; A/Johannesburg/92/1996; A/New Caledonia/20/1999; A/Solomon Islands/3/2006, or an H2 protein from any of the strains: A/Japan/305+/1957; A/Singapore/1/1957; A/Taiwan/1/1964; A/Taiwan/1/1967, or an H3 protein from any of the strains: A/Aichi/2/1968; A/Phillipines/2/1982; A/Mississippi/1/1985; A/Leningrad/360/1986; A/Sichuan/2/1987; A/Shanghai/11/1987; A/Beiging/353/1989; A/Shandong/9/1993; A/Johannesburg/33/1994; A/Nanchang/813/1995; A/Sydney/5/1997; A/Moscow/10/1999; A/Panama/2007/1999; A/Fujian/411/2002; A/Wyoming/3/2003; A/Oklahoma/323/2003; A/California/7/2004; A/Wisconsin/65/2005, wherein the binding agent binds to umbrella-topology glycans.

### Claim 30 (depends on 28, 29)

The antibody of claim 28 or claim 29, which antibody is polyclonal.

### Claim 31 (depends on 28, 29)

The antibody of claim 28 or claim 29, which antibody is monoclonal.

### Claim 32

A viral particle including an engineered binding agent that binds to umbrella-topology glycans.

### Claim 33

A method of treating influenza infection by administering a composition comprising an engineered binding agent that binds to umbrella-topology glycans, a polypeptide comprising a characteristic fragment of an engineered binding agent that binds to umbrella-topology glycans, an antibody that binds to an engineered binding agent that binds to umbrella-topology glycans, or characteristic portion thereof, a nucleic acid that encodes an engineered binding agent that binds to umbrella-topology glycans or characteristic portion thereof, or combinations thereof.

### Claim 34

A glycan array comprising glycan structures of at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% 95%, or more of glycans found on HA receptors in human upper respiratory tract tissues.

### Claim 35 (depends on 26)

A method for identifying or characterizing binding agents, the method comprising steps of:
providing a sample containing a test binding agent;
contacting the sample with the glycan array of claim 26; and
detecting binding of the test binding agent to one or more glycans on the array.

### Claim 36 (depends on 35)

The method of claim 35, wherein the binding agent is an HA polypeptide.

### Claim 37

A method of any of, inhibiting, in a subject, binding of an influenza virus to a hemagglutinin receptor having an umbrella topology, minimizing the risk of infection of a subject by an influenza virus which binds a hemagglutinin receptor having an umbrella topology, or treating a subject, comprising:
identifying a subject susceptible to or suffering from infection by an influenza virus (optionally on the basis of need for blocking an influenza virus which binds a hemagglutinin receptor having an umbrella topology, or on the basis of being at risk for infection by an influenza virus which binds a hemagglutinin receptor having an umbrella topology);
optionally, selecting a binding agent on the basis of the binding agent being able to bind a hemagglutinin receptor having umbrella topology glycans;
optionally, providing a binding agent;
administering an effective amount of the binding agent to the subject, so that binding by the virus to hemagglutinin receptors having umbrella topology glycans is reduced, the risk is minimized, or the patient is treated.

### Claim 38 (depends on 37)

The method of claim 37, wherein the binding agent is an LSBA

### Claim 39 (depends on 37)

The method of claim 37, wherein the binding agent is a UTBA.

### Claim 40 (depends on 37)

The method of claim 37, wherein the binding agent is a UTSBA.

### Claim 41 (depends on 40)

The method of claim 40, wherein the UTSBA is administered to the subject prior to exposure to the virus.

### Claim 42 (depends on 40)

The method of claim 40, wherein the UTSBA is administered to the subject after exposure to the virus.

### Claim 43 (depends on 40)

The method of claim 40, wherein amount administered is sufficient to saturate the subject's HA receptors containing umbrella topology glycans.

### Claim 44 (depends on 40)

The method of claim 40, wherein the UTSBA is administered by inhalation.

### Claim 45 (depends on 44)

The method of claim 44, wherein the UTSBA is administered as an aerosol.

### Claim 46 (depends on 44)

The method of claim 44, wherein the UTSBA is administered as a preparation of particles having a mean particle size of at least 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13 microns.

### Claim 47 (depends on 44)

The method of claim 44, wherein the UTSBA is administered as a dry powder.

### Claim 48 (depends on 44)

The method of claim 44, wherein the UTSBA is administered as a powder treated with a wetting agent.

### Claim 49 (depends on 48)

The method of claim 48, wherein the wetting agent is water, saline, or of physiological pH.

### Claim 50 (depends on 44)

The method of claim 44 wherein the UTSBA is administered with an excipient.

### Claim 51 (depends on 44)

The method of claim 44, wherein less than 1%, 2%, 5%, 10%, 20%, or 30%, by dry weight or number, of the UTSBA administered is present in an aggregate.

### Claim 52 (depends on 44)

The method of claim 44, wherein less than 1%, 2%, 5%, 10%, 20%, or 30%, by dry weight or number, of the UTSBA administered is denatured.

### Claim 53 (depends on 44)

The method of claim 44, wherein less than 1%, 2%, 5%, 10%, 20%, or 30%, by dry weight or number, of the UTSBA administered is inactive.

### Claim 54 (depends on 40)

The method of claim 40, wherein the UTSBA is administered as drops to the nasal or buccal cavity, e.g., in a dose of 1-100, 1-50, or 1-20 drops.

### Claim 55 (depends on 44)

The method of claim 44, wherein the UTSBA is administered from a device which delivers a metered dosage of the UTSBA.

### Claim 56 (depends on 40)

The method of claim 40, wherein the UTSBA is an HA polypeptide.

### Claim 57 (depends on 37)

The method of claim 37, wherein the binding agent is a peptide, e.g., a recombinant polypeptide, having substantial homology with a naturally occurring HA, or fragment thereof, which naturally occurring HA binds an HA receptor having umbrella topology glycans, e.g., an UTHAr having the umbrella topology glycan 6′ SLN-LN, with at least 2, 4, 5, or 10 times the affinity with which it binds to an HA receptor having cone topology glycans, e.g., having the cone topology glycan 3′ SLN-LN.

### Claim 58 (depends on 57)

The method of claim 57, wherein the naturally occurring HA is a H1, H2, or H3.

### Claim 59 (depends on 58)

The method of claim 58, wherein the naturally occurring HA is from the H3 Wyoming isolate.

### Claim 60 (depends on 57)

The method of claim 57, wherein the blocking agent is a recombinant naturally occurring HA or fragment thereof.

### Claim 61 (depends on 57)

The method of claim 57, wherein the blocking agent is a recombinant H1, H2, H3, or fragment thereof.

### Claim 62 (depends on 57)

The method of claim 57, wherein the blocking agent is a recombinant HA from the H3 Wyoming isolate or fragment thereof.

### Claim 63 (depends on 57)

The method of claim 57, wherein the naturally occurring HA is from the H_NY198 isolate.

### Claim 64 (depends on 57)

The method of claim 57, wherein the blocking agent is a recombinant HA from the NY1918 isolate or fragment thereof.

### Claim 65 (depends on 40)

The method of claim 40, wherein the USTBA is a recombinant HA, or fragment thereof, having substantial homology with the naturally occurring HA, which differs from the naturally occurring HA sequence by at least one amino acid, and wherein the naturally occurring HA binds an HA receptor having cone topology glycans, e.g., a CTHAr having the cone topology glycan, 3′ SLN-LN, with at least 2, 4, 5, or 10 time the affinity with which it binds to a HA receptor having umbrella topology glycans (e.g., having the umbrella topology glycan, 6′ SLN-LN.

### Claim 66 (depends on 65)

The method of claim 65, wherein the naturally occurring HA is H5, H7, H9.

### Claim 67 (depends on 65)

The method of claim 65, wherein the USTBA differs from a parent naturally occurring HA at one or more of residues 137, 145, 156, 159, 186, 187, 189, 190, 192, 193, 196, 222, 225, 226, and 228.

### Claim 68 (depends on 65)

The method of claim 65, wherein the USTBA differs from a parent naturally occurring HA at positions corresponding to one or more of residues 156, 159, 189, 192, 193, and 196; and/or at positions corresponding to one or more of residues 186, 187, 189, and 190; and/or at positions corresponding to one or more of residues 190, 222, 225, and 226; and/or at positions corresponding to one or more of residues 137, 145, 190, 226 and 228.

### Claim 69 (depends on 65)

The method of claim 65, wherein the USTBA differs from a parent naturally occurring HA in that the USTBA has sequence substitutions at positions corresponding to one or more of residues 190, 225, 226, and 228.

### Claim 70 (depends on 65)

The method of claim 65, wherein the USTBA differs from a parent naturally occurring HA in that the USTBA has one or more amino acid substitutions at residues selected from the group consisting of residues 98, 136, 138, 153, 155, 159, 183, 186, 187, 190, 193, 194, 195, 222, 225, 226, 227, and 228.

### Claim 71 (depends on 65)

The method of claim 65, wherein the USTBA differs from a parent naturally occurring HA in that the USTBA has one or more amino acid substitutions at residues selected from the group consisting of residues 98, 136, 153, 155, 183, 190, 193, 194, 222, 225, 226, 227, and 228.

### Claim 72 (depends on 65)

The method of claim 65, wherein the USTBA differs from a parent naturally occurring HA in that the USTBA has one or more amino acid substitutions at residues selected from the group consisting of residues 98, 138, 186, 187, 195, and 228.

### Claim 73 (depends on 65)

The method of claim 65, wherein the USTBA differs from a parent naturally occurring HA in that the USTBA has one or more amino acid substitutions at residues selected from the group consisting of residues 138, 186, 187, 190, 193, 222, 225, 226, 227 and 228.

### Claim 74 (depends on 65)

The method of claim 65, wherein the USTBA differs from a parent naturally occurring HA in that the USTBA has one or more amino acid substitutions at residues selected from the group consisting of residues 190, 193, 222, 225, 226, 227, and 228.

### Claim 75 (depends on 65)

The method of claim 65, wherein the USTBA differs from a parent naturally occurring HA in that the USTBA has one or more amino acid substitutions at residues selected from the group consisting of residues 138, 186, 187, and 228.

### Claim 76 (depends on 65)

The method of claim 65, wherein the USTBA differs from a parent naturally occurring HA in that the USTBA has one or more amino acid substitutions at residues selected from the group consisting of residues 98, 136, 153, 155, 183, 194, and 195.

### Claim 77 (depends on 65)

The method of claim 65, wherein the USTBA differs from a parent naturally occurring HA in that the USTBA has one or more amino acid substitutions at residues selected from the group consisting of residues 98, 136, 153, 155, 183, and 194.

### Claim 78 (depends on 65)

The method of claim 65, wherein the USTBA differs from a parent naturally occurring HA in that the USTBA has one or more amino acid substitutions at residues selected from the group consisting of residues 98 and 195.

### Claim 79 (depends on 65)

The method of claim 65, wherein the USTBA differs from a parent naturally occurring HA in that the USTBA has one or more amino acid substitutions at residues selected from the group consisting of residues 98, 138, 186, 187, 195, and 228.

### Claim 80 (depends on 65)

The method of claim 65, wherein the USTBA differs from a parent naturally occurring HA in that the USTBA has one or more amino acid substitutions at residues selected from the group consisting of residues 138, 186, 187, and 228.

### Claim 81 (depends on 65)

The method of claim 65, wherein the USTBA differs from a parent naturally occurring HA in that the USTBA has one or more amino acid substitutions at residues selected from the group consisting of residues 98 and 195.

### Claim 82 (depends on 65)

The method of claim 65, wherein the USTBA differs from a parent naturally occurring HA in that the USTBA has one or more amino acid substitutions at residue 159.

### Claim 83 (depends on 65)

The method of claim 65, wherein the USTBA differs from a parent naturally occurring HA in that the USTBA has one or more amino acid substitutions at residues selected from the group consisting of residues 190, 193, 226, and 228.

### Claim 84 (depends on 65)

The method of claim 65, wherein the USTBA differs from a parent naturally occurring HA in that the USTBA has one or more of the following amino acid substitutions: Ser137Ala, Lys156Glu, Asn186Pro, Asp187Ser, Asp187Thr, Ala189Gln, Ala189Lys, Ala189Thr, Glu190Asp, Glu190Thr, Lys193Arg, Lys193Asn, Lys193His, Lys193Ser, Gly225Asp, Gln226Ile, Gln226Leu, Gln226Val, Ser227Ala, Gly228Ser.

### Claim 85 (depends on 65)

The method of claim 65, wherein the USTBA differs from a parent naturally occurring HA in that the USTBA has one or more of the following amino acid substitutions:
Glu190Asp, Lys193Ser, Gly225Asp and Gln226Leu;
Glu190Asp, Lys193Ser, Gln226Leu and Gly228Ser;
Ala189Gln, Lys193Ser, Gln226Leu, Gly228Ser;
Ala189Gln, Lys193Ser, Gln226Leu, Gly228Ser;
Asp187Ser/Thr, Ala189Gln, Lys193Ser, Gln226Leu, Gly228Ser;
Ala189Lys, Lys193Asn, Gln226Leu, Gly228Ser;
Asp187Ser/Thr, Ala189Lys, Lys193Asn, Gln226Leu, Gly228Ser;
Lys156Glu, Ala189Lys, Lys193Asn, Gln226Leu, Gly228Ser;
Lys193His, Gln226Leu/Ile/Val, Gly228 Ser;
Lys193Arg, Gln226Leu/Ile/Val, Gly228 Ser;
Ala189Lys, Lys193Asn, Gly225Asp;
Lys156Glu, Ala189Lys, Lys193Asn, Gly225Asp;
Ser137Ala, Lys156Glu, Ala189Lys, Lys193Asn, Gly225Asp;
Glu190Thr, Lys193Ser, Gly225Asp;
Asp187Thr, Ala189Thr, Glu190Asp, Lys193Ser, Gly225Asp;
Asn186Pro, Asp187Thr, Ala189Thr, Glu190Asp, Lys193Ser, Gly225Asp;
Asn186Pro, Asp187Thr, Ala189Thr, Glu190Asp, Lys193Ser, Gly225Asp, Ser227Ala.

### Claim 86 (depends on 65)

The method of claim 65, wherein the USTBA is an HA polypeptide having an amino acid sequence that includes D190, D225, L226, and/or S228.

### Claim 87 (depends on 65)

The method of claim 65, wherein the USTBA is an HA polypeptide having an amino acid sequence that includes D190 and D225.

### Claim 88 (depends on 65)

The method of claim 65, wherein the USTBA is an HA polypeptide having an amino acid sequence that includes L226 and S228.

### Claim 89 (depends on 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88)

The method of any one of claims 67-88 wherein the USTBA is an H5 polypeptide.

### Claim 90 (depends on 40)

The method of claim 40, wherein the antibody is a monoclonal, monospecific, chimeric, CDR grafted, humanized, human, cameloid, IgNAR, single chain, IgA, IgM, IgG, etc.

### Claim 91 (depends on 40)

The method of claim 40, wherein the UTSBA is a lectin, e.g., SNA-1.

### Claim 92 (depends on 40)

The method of claim 40, wherein the UTSBA is a non-HA polypeptide.

### Claim 93 (depends on 40)

The method of claim 40, wherein the UTSBA is a small molecule.

### Claim 94 (depends on 40)

The method of claim 40, wherein the UTSBA is a lectin.

### Claim 95 (depends on 40)

The method of claim 40, wherein the blocking agent is provided in a preparation which is formulated for delivery by inhalation.

### Claim 96 (depends on 40)

The method of claim 40, wherein the UTSBA agent is provided in a preparation which is essentially free of adjuvants, e.g., an alum adjuvant.

### Claim 97 (depends on 40)

The method of claim 40, wherein the UTSBA is provided in a preparation which is essentially free of other HA polypeptides, e.g., other HA polypeptides which bind to HA receptor glycans other than an umbrella topology glycan.

### Claim 98 (depends on 40)

The method of claim 40, wherein the UTSBA is provided in a preparation having no more than 50, 40, 30, 20, 10, 5, or 1% by number or weight, an agent which binds to HA receptor glycans other than and umbrella topology glycans.

### Claim 99 (depends on 40)

The method of claim 40, wherein the umbrella topology glycan comprises oligosaccharides of the following form:
Neu5Acα2-6Sug1-Sug2-Sug3
where:
(a) Neu5Ac α2-6 is typically (but not essentially) at the non-reducing end;
(b) Sug1:
(i) is a hexose (frequently Gal or Glc) or hexosamine (GlcNAc or GalNAc) in α or β configuration (frequently β- for N- and O-linked extension and α- in the case of GalNAcα- that is O-linked to glycoprotein);
(ii) no sugars other than Neu5Acα2-6 are attached to any of the non-reducing positions of Sug1 (except when Sug1 is GalNAcα- that is O-linked to the glycoprotein); and/or
(iii) non-sugar moieties such as sulfate, phosphate, guanidium, amine, N-acetyl, etc. can be attached to non-reducing positions (typically 6 position) of Sug1 (e.g., to improve contacts with HA);
(c) Sug2 and/or Sug3 is/are:
(i) hexose (frequently Gal or Glc) or hexosamine (GlcNAc or GalNAc) in α or β configuration (frequently β); and/or
(ii) sugars (such as Fuc) or non-sugar moieties such as sulfate, phosphate, guanidium, amine, N-acetyl, etc. can be attached to non-reducing positions of Sug2, Sug3, and/or Sug4;
(d) Linkage between any two sugars in the oligosaccharide apart from Neu5Acα2-6 linkage can be 1-2, 1-3, 1-4, and/or 1-6 (typically 1-3 or 1-4); and/or
(e) Structure where Neu5Acα2-6 is linked GalNAcα that is O-linked to the glycoprotein and additional sugars are linked to the non-reducing end of GalNAcα for example
(i) Neu5Acα2-6(Neu5Acα2-3Galβ1-3)GalNAcα-
(ii) Neu5Acα2-6(Galβ1-3)GalNAcα-

### Claim 100 (depends on 40)

The method of claim 40, wherein said UTSBA is administered in combination with administration of a second therapeutic, e.g., an anti-viral agent, e.g., Oseltamivir (Tamiflu), Zanamavir (Releza), or a sialydase.

### Claim 101 (depends on 40)

The method of claim 40, wherein the UTSBA is associated with, e.g., bound to a polymer, e.g., PEG or carboxymethyl cellulose, the UTSBA has additional glycosylation, or the UTSBA, e.g., to minimize an immune response to the UTSBA.

### Claim 102 (depends on 40)

The method of claim 40, wherein the UTSBA is administered so as to minimize an immune response.

### Claim 103 (depends on 40)

The method of claim 40, wherein the UTSBA is administered continuously, e.g., administered without a period of less than therapeutic level interposed between two periods of therapeutic level.

### Claim 104 (depends on 40)

The method of claim 40, wherein the UTSBA is administered continuously, e.g., daily or multi daily doses for each day of treatment.

### Claim 105 (depends on 40)

The method of claim 40, wherein at least one amino acid residue has been altered so as to reduce immunogenicity.

### Claim 106 (depends on 40)

The method of claim 40, wherein the UTSBA is multivalent.

### Claim 107 (depends on 40)

The claim of claim 40, wherein the UTSBA is multivalent and binds 2, 3, 4, 6, 7, 8, 9, or 10 or more umbrella topology glycans.

### Claim 108 (depends on 40)

The method of claim 40, further comprising administering a second USTBA, e.g., administering an H1 and an H3 based UTSBA.

### Claim 109

A method of selecting a subject for treatment with a blocking agent comprising:
identifying a subject suffering from or susceptible to influenza infection, or optionally, identifying a subject on the basis of need for blocking an HA receptor having an umbrella topology glycan or on the basis of being at risk for infection by an influenza virus which binds an HA receptor having an umbrella topology glycan;
administering the blocking agent to the subject or selecting a dosage of the blocking agent for the subject;
thereby selecting a subject for treatment with a bl-ocking agent.

### Claim 110 (depends on 109)

The method of claim 109, wherein the blocking agent is an LSBA.

### Claim 111 (depends on 109)

The method of claim 109, wherein the blocking agent is a UTBA.

### Claim 112 (depends on 109)

The method of claim 109, wherein the blocking agent is a UTSBA.

### Claim 113 (depends on 109)

The method of claim 109, further comprising memorializing the selection of the subject.

### Claim 114 (depends on 109)

The method of claim 109, further comprising classifying a dose of UTSBA as being for use of said subject.

### Claim 115 (depends on 109)

The method of claim 109, further comprising notifying the subject of the selection.

### Claim 116

A method of selecting a patient for treatment with blocking agent comprising:
optionally, identifying a subject suffering from or susceptible to influenza infection;
determining if the subject has antibodies that react with a blocking agent;
if the subject lacks antibodies to the a blocking agent, selecting the subject for treatment, thereby selecting a patient for treatment with a blocking agent.

### Claim 117 (depends on 116)

The method of claim 116, wherein the blocking agent is an LSBA.

### Claim 118 (depends on 116)

The method of claim 116, wherein the blocking agent is a UTBA.

### Claim 119 (depends on 116)

The method of claim 116, wherein the blocking agent is a UTSBA.

### Claim 120 (depends on 119)

The method of claim 119, further comprising administering the UTSBA to the subject.

### Claim 121 (depends on 119)

The method of claim 119, further comprising classifying a dose of UTSBA as being for use of said subject.

### Claim 122

A method of selecting a dosage of a blocking agent, comprising:
optionally, identifying a subject suffering from or susceptible to influenza infection, e.g., identifying a subject on the basis of need for blocking an HA receptor having an umbrella topology glycan or on the basis of being at risk for infection by an influenza virus which binds an HA receptor having an umbrella topology glycan;
determining if the subject has antibodies that react with a blocking agent;
selecting a subject or dose based on the determination, thereby selecting a dosage for treatment with a blocking agent.

### Claim 123 (depends on 122)

The method of claim 122, wherein the blocking agent is an LSBA.

### Claim 124 (depends on 122)

The method of claim 122, wherein the blocking agent is a UTBA.

### Claim 125 (depends on 122)

The method of claim 122, wherein the blocking agent is a UTSBA.

### Claim 126 (depends on 125)

The method of claim 125, further comprising administering the UTSBA to the subject.

### Claim 127 (depends on 126)

The method of claim 126, further comprising classifying a dose of UTSBA as being for use of said subject.

### Claim 128

A method of selecting a drug for administration to a subject comprising:
identifying a subject suffering from or susceptible to influenza infection, or optionally, identifying a subject on the basis of need for blocking an HA receptor having an umbrella topology glycan or on the basis of being at risk for infection by an influenza virus which binds an HA receptor having an umbrella topology glycan;
selecting a blocking agent on the basis that it blocks an UTHAr;
optionally, providing a unit dose of a blocking agent to the subject or to a health care provider for administration to the subject.
thereby selecting a drug for administration to a subject.

### Claim 129 (depends on 128)

The method of claim 128, wherein the blocking agent is an LSBA.

### Claim 130 (depends on 128)

The method of claim 128, wherein the blocking agent is a UTBA.

### Claim 131 (depends on 128)

The method of claim 128, wherein the blocking agent is a UTSBA

### Claim 132 (depends on 131)

The method of claim 131, further comprising administering the UTSBA to the subject.

### Claim 133 (depends on 132)

The method of claim 132, further comprising classifying a dose of UTSBA as being for use of said subject.

### Claim 134 (depends on 132)

The method of claim 132, further comprising memorializing the selection of the USTBA.

### Claim 135

A method of evaluating a test binding agent, e.g., a polypeptide, e.g., naturally occurring or mutant HA, or an antibody, e.g., for use in minimizing risk of infection with by avian influenza comprising,
determining the ability of the agent to bind, e.g., specifically bind, to a HA having an umbrella topology glycan,
thereby evaluating the agent.

### Claim 136

A device containing a blocking agent and configured to administer a dose, e.g., a metered dose, of the blocking agent, to the respiratory tract of a subject.

### Claim 137 (depends on 136)

The device of claim 136, wherein the blocking agent is provided in the form of a pharmaceutical composition described herein.

### Claim 138 (depends on 136)

The device of claim 136, further containing a second agent, e.g., an anti-viral agent, e.g., Oseltamivir (Tamiflu), Zanamavir (Releza), or a sialydase.

### Claim 139

A kit comprising an initial unit dose and a subsequent unit dose of a binding agent, e.g., an HA polypeptide, a LSBA, an UTBA, an UTSBA, wherein the initial unit dose is greater than the subsequent unit dose or where the two doses are equal.

### Claim 140 (depends on 139)

The kit of claim 139, further comprising at least one component of a delivery device, e.g., an inhaler.

### Claim 141

A kit comprising at least one component of a delivery device, e.g., an inhaler and a dose of an of a binding agent.

### Claim 142

A kit comprising a dose of an of a binding agent.

### Claim 143 (depends on 141, 142)

The kit of claim 141 or 142, further comprising instructions for use.

### Claim 144

A pharmaceutical composition comprising a binding agent.

### Claim 145 (depends on 57, 144)

The pharmaceutical composition of claim 144, wherein the binding agent is the binding agent of claim 57.

### Claim 146 (depends on 65, 144)

The pharmaceutical composition of claim 144, wherein the binding agent is the binding agent of claim 65.

### Claim 147 (depends on 70, 144)

The pharmaceutical composition of claim 144, wherein the binding agent is the binding agent of claim 70.

### Claim 148 (depends on 144)

The pharmaceutical composition of claim 144, wherein the antibody is a monoclonal, monospecific, chimeric, CDR grafted, humanized, human, cameloid, IgNAR, single chain, IgG, etc.

### Claim 149 (depends on 144)

The pharmaceutical composition of claim 144, wherein said composition is suitable for inhalation.

### Claim 150 (depends on 144)

The pharmaceutical composition of claim 144, wherein said composition further comprises a second agent, e.g., an anti-viral agent, e.g., Oseltamivir (Tamiflu), Zanamavir (Releza), or a sialydase.

### Claim 151 (depends on 144)

The pharmaceutical composition of claim 144, wherein said composition is substantially free of an adjuvant.

### Claim 152 (depends on 144)

The pharmaceutical composition of claim 144, wherein the blocking agent is an HA polypeptide and the composition is substantially free of any other HA polypeptides, e.g., other HA polypeptides which bind to HA receptor glycans other than an umbrella topology glycan.

### Claim 153 (depends on 144)

The pharmaceutical composition of claim 144, wherein the blocking agent is provided in a preparation having no more than 50, 40, 30, 20, 10, 5, or 1% by number or weight, an agent which binds to HA receptor glycans other than and umbrella topology glycans.

### Claim 154 (depends on 144)

The pharmaceutical composition of claim 144, wherein the blocking agent has a preselected affinity for a 2-6 glycan having an umbrella topology and a preselected affinity for 2-6 glycan having a cone topology.

### Claim 155

A pharmaceutical composition comprising a first binding agent and a second binding agent.

### Claim 156

A pharmaceutical compositions comprising an umbrella topology binding agent and a cone topology binding agent, e.g., a recombinant HA or fragment thereof which binds an HA receptor having a cone topology glycan, e.g., a 2-6 glycan having a cone topology.
